COMMUNIQUÉS West-GlobeNewswire

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29/01/2024
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]
Range Impact Announces Former Ohio Congressman Zack Space and Former Ohio Senator Jay Hottinger Have Joined the Company as Strategic Advisors
29/01/2024
CLEVELAND, OHIO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public company dedicated to improving the health and wellness of people and the planet through a novel and innovative [...]
Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling
29/01/2024
Doheny Eye Institute scientists in collaboration with UCLA Chemists show how a single gene mutation in an enzyme complex known to produce the energy required by cells causes a sudden, blinding disease PASADENA, Calif., [...]
MatrixCare Forges Strategic Partnership with Tranzion, a Subsidiary of NHC, to Expand EHR Services for Senior Living Medical Providers
29/01/2024
BLOOMINGTON, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- MatrixCare, a global technology leader in the post-acute space, is proud to announce its strategic partnership with Tranzion, a newly established subsidiary of NHC ( [...]
Alberta Cancer Foundation announces matching gift campaign with goal of raising $400,000 in support of Patient Financial Assistance Program
29/01/2024
This World Cancer Day, donations to Alberta Cancer Foundation make double the impact, helping thousands of Albertans facing cancer make ends meet EDMONTON, Alberta, Jan. 29, 2024 (GLOBE NEWSWIRE) -- February 4, 2024 [...]
Accelus Introduces LineSider Modular-Cortical System for Posterior Fixation
29/01/2024
Continued expansion of LineSider Spinal System portfolio offers surgeons increased visibility and versatility PALM BEACH GARDENS, Fla., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Accelus , a privately held medical technology [...]
Trading by management and close relations of management
29/01/2024
January 29, 2024 Company announcement No. 04 Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse [...]
Spectral Submits Application for UKCA Mark Classification
29/01/2024
DALLAS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (NASD: MDAI; MDAIW) (“Spectral AI” or the “Company ”) , an artificial intelligence (AI) company focused on medical [...]
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
29/01/2024
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications BOSTON and [...]
LTC ACO Continues Growth With Five Additional Provider Partners for Performance Year 2024
29/01/2024
New participants to transition to value-based care, improving quality and cost performance KENNETT SQUARE, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- LTC ACO , the first and only Accountable Care Organization (ACO) in the U [...]
Earth Science Tech, Inc., Announces $5 Million Common Stock Repurchase Program
29/01/2024
Miami, FL, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a holding entity currently focused on the health and wellness industry, today announces that its Board of [...]
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
29/01/2024
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in [...]
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
29/01/2024
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to [...]
Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer
29/01/2024
SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular [...]
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
29/01/2024
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA [...]
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
29/01/2024
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Privia Health Appoints Edward C. Fargis as General Counsel
29/01/2024
ARLINGTON, Va., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that Edward C. Fargis has been named Executive Vice President, General Counsel and Corporate Secretary, effective [...]
Sirona Biochem Announces Loan
29/01/2024
VANCOUVER, British Columbia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ” or the “ Company ”) announced that it has entered into a demand grid promissory note [...]
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
29/01/2024
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, [...]

Pages